Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Filed with HKEX · Stock code 2157 · · 10 pages · English
Summary by 6ix AI
It confirms the total authorised and registered share capital at the end of the month. The report also includes a public float sufficiency confirmation, indicating compliance with applicable requirements. The document serves to inform the Hong Kong Exchanges and Clearing Limited about the company's securities movements.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Lepu Biopharma Co. Ltd. on 6ix
Earlier from Lepu Biopharma
- Voluntary announcement four clinical studies selected for presentation at 2026 ESMO congress: CMG901 (AZD0901) clinical trial results selected as LBA for proffered paper presentation at Presidential Symposium, MRG007 clinical trial results selected as LBA for rapid oral presentation, and two other studies selected for rapid oral presentation
- 2026 Interim Report
- BioDlink and Lepu Biopharma Celebrate Successful Launch of the World's First EGFR-Targeting ADC Drug, Marking a Major Milestone in Mutual Collaboration in Biologics CMC
- BioDlink Congratulates Lepu Biopharma on Securing Approval for the World's First Approved EGFR-Targeted ADC
Follow Lepu Biopharma into a list and get an email when it puts out news.
Follow Lepu Biopharma